

Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/MDF188CAE20EEN.html>

Date: December 2022

Pages: 121

Price: US\$ 2,000.00 (Single User License)

ID: MDF188CAE20EEN

Abstracts

Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2022, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 22, 23 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 11 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Middle East Respiratory Syndrome (MERS) - Overview

Middle East Respiratory Syndrome (MERS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development

Middle East Respiratory Syndrome (MERS) - Drug Profiles

Middle East Respiratory Syndrome (MERS) - Dormant Projects

Middle East Respiratory Syndrome (MERS) - Discontinued Products

Middle East Respiratory Syndrome (MERS) - Product Development Milestones

Featured News & Press Releases

Oct 31, 2022: EpiVax joins Intravacc, CEPI on project to develop universal betacoronavirus vaccine

Nov 04, 2021: Vaccitech announces publication of second phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirus

Jun 14, 2021: Announcement of the effect of OBP-2011 against SARS and MERS

Feb 23, 2021: Monoclonal antibody REGN3051 against MERS coronavirus show promise in Phase 1 NIH-sponsored trial

Feb 23, 2021: Monoclonal antibody REGN3048 against MERS coronavirus show promise in Phase 1 NIH-sponsored trial

Jan 27, 2020: Pulmotect's PUL-042 shows promising pre-clinical efficacy in preventing lethal coronavirus infection

Dec 20, 2019: New MERS vaccine clinical trial starts in Saudi Arabia

Sep 29, 2018: Vaccitech licenses MERS rights to Oxford University: CEPI awards contract worth up to USD\$19 million to Oxford University and Janssen vaccines to develop MERS, Lassa, and Nipah vaccines

Mar 05, 2018: Hemispherx to Present Alferon N Injection at the 30th Annual ROTH

Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Middle East Respiratory Syndrome (MERS) - Dormant Projects, 2022

Middle East Respiratory Syndrome (MERS) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/MDF188CAE20EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDF188CAE20EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

